Zaxoran

Zaxoran is indicated in adult patients with type 2 diabetes mellitus:

• as an adjunct to dietary measures and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled with the maximum tolerated dose of metformin alone or in patients already treated with the combination of sitagliptin and metformin.
• for combination with sulfonylurea derivatives (i.e., triple combination therapy) as an adjunct to dietary measures and exercise in patients whose diabetes is not adequately controlled with the maximum tolerated dose of metformin and sulfonylurea derivatives.
• for triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (e.g. thiazolidinedione) as an adjunct to diet and exercise in patients whose diabetes is not adequately controlled with the maximum tolerated dose of metformin and a PPARγ agonist.
• as additional therapy to insulin therapy (i.e. triple combination therapy) in addition to dietary measures and exercise to improve glycaemic control in patients when a stable dose of insulin and metformin alone does not provide adequate glycaemic control.